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Background
RAD21 is a central component of the multi-protein
cohesin complex which is important in several key cellu-
lar processes; apposition of sister chromatids, chromoso-
mal segregation during mitosis and meiosis, error free
homologous recombinational repair of DNA double
strand breaks and epigenetic regulation of gene expres-
sion. Components of the cohesin complex are of the
‘BASC’, a BRCA1-associated multiprotein DNA repair
complex. Aberrant RAD21 expression has been reported
in several cancers with overexpression associated with
more aggressive clinical course and chemo-resistance. In
vitro cell lines and tumour xenografts of prostate can-
cers have shown overexpression of RAD21 compared
with benign epithelium. Located at 8q24, this also
appears to be a region often amplified in aggressive
prostate cancer in vivo. We examined for RAD21
expression in familial prostate cancer.
Methods
TMAs were created from 40 prostate cancer samples
including 11 BRCA2 and 13 BRCAX associated
tumours. IHC staining for RAD21 was correlated with
E-cadherin, b-catenin, Androgen Receptor (AR), MUC1,
AMACAR, Cyclin-D1 and clinico-histological factors.
Results
53% of tumours overexpressed RAD21, with a higher
proportion of BRCA-X tumours (80%, p=0.0082) com-
pared with BRCA2 and sporadic cancers. RAD21 was
positively correlated with Ki-67 (p=0.0053) and inversely
with aberrant E-cadherin expression (p=0.0323). Within
the sporadic/non-BRCA2/X tumour group, there was
positive correlation with AR (0.0070) and Cyclin-D1
(p=0.0270).
Conclusion
RAD21 expression is commonly present in prostate car-
cinoma and may be particularly important in the patho-
genesis of BRCAX associated tumours. Within sporadic
non-BRCA associated tumours, there is an association
between RAD21 and AR expression, which may be bio-
logically relevant and distinct in pathogenesis from
those with aberrant E-cadherin expression.
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